Alignment Healthcare, Inc. ALHC
We take great care to ensure that the data presented and summarized in this overview for Alignment Healthcare, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALHC
View all-
General Atlantic LLC New York, NY61MShares$714 Million15.09% of portfolio
-
Warburg Pincus LLC New York, NY17.9MShares$210 Million8.64% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY10.9MShares$128 Million1.79% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.59MShares$112 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.19MShares$95.9 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.03MShares$94.1 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA4.5MShares$52.7 Million0.01% of portfolio
-
Durable Capital Partners LP Bethesda, MD3.98MShares$46.6 Million0.27% of portfolio
-
Hood River Capital Management LLC Palm Beach Gardens, FL3.11MShares$36.4 Million0.59% of portfolio
-
William Blair Investment Management, LLC Chicago, IL3.1MShares$36.4 Million0.07% of portfolio
Latest Institutional Activity in ALHC
Top Purchases
Top Sells
About ALHC
Alignment Healthcare, Inc., a tech-enabled Medicare advantage company, operates consumer-centric health care platform. It provides customized health care in the United States to seniors and those who need it through its Medicare advantage plans. The company owns Medicare advantage plans in the states of California, North Carolina, and Nevada. It also coordinates and provides covered health care services, including professional, institutional, and ancillary services to members enrolled in certain benefit plans of unaffiliated Medicare Advantage Health Maintenance Organizations. The company was founded in 2013 and is based in Orange, California.
Insider Transactions at ALHC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 15
2024
|
Dawn Christine Maroney President, Markets |
SELL
Open market or private sale
|
Direct |
30,000
-1.71%
|
$300,000
$10.77 P/Share
|
Oct 14
2024
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
30,500
-15.67%
|
$335,500
$11.5 P/Share
|
Oct 09
2024
|
John E Kao Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
90,000
-3.42%
|
$990,000
$11.33 P/Share
|
Oct 08
2024
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
39,320
-16.81%
|
$471,840
$12.04 P/Share
|
Oct 08
2024
|
Hyong Kim Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
22,460
-4.04%
|
$247,060
$11.03 P/Share
|
Oct 02
2024
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
9,125
-3.75%
|
$100,375
$11.01 P/Share
|
Oct 01
2024
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
21,375
-4.13%
|
$213,750
$10.75 P/Share
|
Oct 01
2024
|
Christopher J Joyce Chief Legal and Admin. Officer |
SELL
Open market or private sale
|
Direct |
667
-0.18%
|
$7,337
$11.79 P/Share
|
Sep 17
2024
|
Joseph S Konowiecki Director |
SELL
Open market or private sale
|
Direct |
16,413
-1.42%
|
$180,543
$11.77 P/Share
|
Sep 16
2024
|
Dawn Christine Maroney President, Markets |
SELL
Open market or private sale
|
Direct |
30,000
-1.68%
|
$330,000
$11.7 P/Share
|
Sep 16
2024
|
John E Kao Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
90,000
-3.31%
|
$990,000
$11.7 P/Share
|
Sep 13
2024
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
14,500
-5.2%
|
$174,000
$12.0 P/Share
|
Sep 13
2024
|
Joseph S Konowiecki Director |
SELL
Open market or private sale
|
Direct |
25,000
-2.11%
|
$300,000
$12.0 P/Share
|
Sep 12
2024
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
120,500
-30.17%
|
$1,325,500
$11.0 P/Share
|
Sep 12
2024
|
Joseph S Konowiecki Director |
SELL
Open market or private sale
|
Direct |
25,000
-2.07%
|
$275,000
$11.0 P/Share
|
Sep 12
2024
|
Hakan Kardes Chief Experience Officer |
SELL
Open market or private sale
|
Direct |
25,000
-6.17%
|
$275,000
$11.48 P/Share
|
Sep 11
2024
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
8,561
-2.1%
|
$85,610
$10.01 P/Share
|
Sep 11
2024
|
Christopher J Joyce Chief Legal and Admin. Officer |
SELL
Open market or private sale
|
Direct |
34,626
-4.41%
|
$311,634
$9.73 P/Share
|
Sep 05
2024
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
4,789
-1.16%
|
$47,890
$10.0 P/Share
|
Sep 05
2024
|
Christopher J Joyce Chief Legal and Admin. Officer |
SELL
Open market or private sale
|
Direct |
4,541
-1.12%
|
$45,410
$10.0 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 2.37M shares |
---|---|
Open market or private purchase | 103K shares |
Open market or private sale | 1.26M shares |
---|---|
Payment of exercise price or tax liability | 34.5K shares |
Bona fide gift | 6K shares |